Khiron Announces Pricing of Marketed Short Form Prospectus Offering of Common Shares

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES/

TORONTO, Aug. 23, 2018 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN , OTCQB:KHRNF), a Canadian integrated medical cannabis company with its core operations in Colombia, is pleased to report that it has priced and sized its previously announced marketed offering of common shares at a price of $0.90 per share to raise aggregate gross proceeds of up to $11,250,000 (the "Offering").

The Offering will be conducted through a syndicate of agents on a best efforts basis led by Canaccord Genuity Corp., and including GMP Securities L.P., Sprott Private Wealth LP, and Cormark Securities Inc. (together, the "Agents").  The Company has also granted the Agents with an over-allotment option to offer and sell up to an additional 15% of the number of common shares sold in the Offering.

In connection with the foregoing, the Company has filed an amended and restated preliminary short form prospectus (the "Prospectus") with the securities regulatory authorities in each of the provinces of Canada, other than Québec.  The Company expects to file the final short form prospectus in respect of the Offering on or about September 6, 2018 and to close the Offering on or about September 13, 2018. The Company intends to use the net proceeds of the Offering in the manner as disclosed in the Prospectus.

The Offering will be subject to certain customary conditions including, but not limited to, the receipt of all necessary approvals, including the approval of the TSX Venture Exchange ("TSXV") and the applicable securities regulatory authorities. A copy of the Prospectus is available on SEDAR under the Company's profile at www.sedar.com.

The common shares subject to the Offering have not been and will not be registered under the U.S. Securities Act of 1933, as amended, (the "U.S. Securities Act") and may not be offered or sold in the United States absent registration under or an applicable exemption from the registration requirements of the U.S. Securities Act. This press release does not constitute an offer to sell or the solicitation of an offer to buy the shares herein described, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

About Khiron Life Sciences Corp.

Khiron Life Sciences Corp. is positioned to be a leading integrated medical cannabis company in Latin America. The Company has core operations in Colombia and is fully licensed in the country for the cultivation, production, domestic distribution, and international export of both tetrahydrocannabinol (THC) and cannabidiol (CBD) medical cannabis. In May 2018, Khiron listed on the TSXV, becoming the first Colombian based medical cannabis company to trade on any exchange globally.

With a focused regional strategy and patient oriented approach, the Company combines global scientific expertise, agricultural advantages, branded product market entrance experience and education to drive prescription and brand loyalty to address priority medical conditions such as chronic pain, epilepsy, depression and anxiety in the Latin American market of over 620 million people. The Company is led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced executive team, and a knowledgeable Board of Directors that includes former President of Mexico, Vicente Fox. 

Forward-looking statements

This news release may contain "forward-looking information" and "forward-looking statements" within the meaning of applicable Canadian securities legislation. All information contained herein that is not historical in nature may constitute forward-looking information. Forward-looking statements herein include but are not limited to statements regarding the Offering, anticipated timing of the filing of the final short form prospectus, the closing of the Offering, the use of proceeds, the receipt of requisite TSXV and securities regulatory approvals, and are necessarily based upon a number of assumptions that, while considered reasonable by management, are inherently subject to business, market and economic risks, uncertainties and contingencies that may cause actual results, performance or achievements to be materially different from those expressed or implied by forward-looking statements. Except as required by law, the Company disclaims any obligation to update or revise any forward-looking statements. Readers are cautioned not to put undue reliance on these forward-looking statements.

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.

Further information in respect of the Company can be found at www.khiron.ca.

SOURCE Khiron Life Sciences Corp.

Investor Contacts: Chris Naprawa, President, T: [phone], E: [email protected]; Darren Collins, Chief Financial Officer, T: [phone], E: [email protected], Media Contact: Jon Packer, Vice President, Communications, T: [phone], E: [email protected]